SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

PSMA PET prognosis, PROMISE registry, PSMA PET survival prediction, prostate cancer prognostic biomarker, PSMA PET risk stratification, Emerging Prognostic Value of Molecular Imaging in Prostate ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to diagnose prostate cancer and a presentation by Dr. Gerhardt Attard discussing molecular tests at diagnosis for ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

ASCO 2025, bladder cancer, Muscle Invasive Bladder Cancer (MIBC), Sasanlimab, SASAN-SPARING trial, Sasanlimab as Bladder-Sparing Maintenance Treatment After Neoadjuvant Chemotherapy, Whole-exome ...